AI Summary
The study discusses a new combined therapy approach for treating multiple sclerosis (MS) using Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The successful Phase I trials have led to plans for Phase II trials to further investigate this promising treatment method.
Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results build on two harmonized Phase I clinical trials, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The team is now preparing to move into Phase II trials to further explore these findings.